A CASE STUDY ON LIFE-THREATENING PREGNANCY-INDUCED HYPERTENSION IN PRETERM PREGNANCY AND MANAGEMENT CHALLENGES
Pregnancy induced hypertension
Pregnancy-induced hypertension (PIH) is life threatening for the mother and her baby. Pre-eclampsia in pregnancy is a multisystem, disorder associated with significant maternal and neonatal morbidity and mortality. The current case study was done to clarify the consequences of PIH as a life-threatening condition at one of the governmental hospitals. A follow-up with observation recording was done since the first admission until the end of treatment duration. The patient presented with life-threatening PIH at 32 weeks of gestation. She was very tired and irritable and stayed in the hospital for several days; the case condition was progressed toward worse, lack of high-risk cases management team, the treatment plan, and decision-making were delayed until the 2nd day in the presence of the senior doctors. The final consequence for the present case was delivered by complicated cesarean section, the uterine repair was done due to placenta accrete and the baby was transferred to the neonatal intensive care unit with low Apgar scoring. The study concluded that early detection and proper intervention with the presence of collaborative team are required to reduce the maternal complications in low resources countries.
2. Kohei H, Yoshitsugu C, Eiji K, Yusuke U, Shunsuke K, Haruta M, et al. Positive-pressure ventilation for preeclampsia-induced pulmonary edema. Case Rep Obstet Gynecol 2018;2018:7274597.
3. Snigdh R, Belind J. Hypertension and pregnancy: Management and future risks. Adv Chronic Kidney Dis 2019;26:137-45.
4. ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002;99:159-67.
5. Karumanchi SA, Maynard S, Sukhatme VP. Methods of treating pre-eclampsia or eclampsia . ??? 2018;9:925-261.
6. Khalifa AE, Farahat MM, Alsaudi KM. Management of women with severe preeclampsia by different regimens of magnesium sulfate. Egypt J Hosp Med 2019;74:1849-56.
7. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control 2015;8:7-12.
8. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
9. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: A systematic review. Lancet 2006;367:1066-74.
10. Khedun SM, Moodley J, Naicker T, Maharaj B. Drug management of hypertensive disorders of pregnancy. Pharmacol Ther 1997;74:221-58.
11. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003;102:181-92.
12. Wagner LK. Diagnosis and management of preeclampsia. Am Fam Physician 2004;70:2317-24.
13. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008;21:521-6.
14. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM. Williams Obstetrics. 24th ed. New York: McGraw-Hill Professional; 2014.
15. Maqbool M, Dar MA, Gani I, Mir SA, Khan M, Bhat AU. Maternal health and nutrition in pregnancy. World J Pharm Pharm 2019;3:450-9.
This work is licensed under a Creative Commons Attribution 4.0 International License.